

Please amend the subject application as follows.

In the claims:

Please cancel claims 1, 54, 55, 63, and 64-86 without prejudice to pursue the subject matter of these claims in a related application. Claims 64-86 are directed non-elected inventions.

For convenience, all pending claims are presented, whether amended or not. Please amend claims 53, 56-57, 59-61, and 87-88 as follows.

Cell
B1 *G7*
--53. (amended) A monoclonal antibody which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, produced by the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12618, HB-12615, or HB-12617, respectively, as deposited with the American Type Culture Collection.

B2
--56. (amended) The monoclonal antibody of claim 53 which is a chimeric antibody.--

--57. (amended) The monoclonal antibody of claim 56, wherein the chimeric antibody is a humanized antibody.--

--58. (not amended) A cell that produces the monoclonal antibody of claim 53.--

--59. (amended) A recombinant protein comprising the antigen binding region of the monoclonal antibody of claim 53.--

B3
--60. (amended) An Fab, F(ab')₂ or Fv fragment of the monoclonal antibody of claim 53.--

B3 cont
--61. (amended) An immunoconjugate comprising a cytotoxic agent and the monoclonal antibody of claim 53. ~~4~~

--62. (not amended) An immunoconjugate comprising a cytotoxic agent and the recombinant protein of claim 59.--

Sub G
B4
--87. (amended) A composition, comprising a pharmaceutically effective amount of the antibody of claim 53 that specifically binds to the extracellular domain of SEQ ID NO.: 2, and a pharmaceutically acceptable carrier. ~~4~~

--88. (amended) A kit comprising the monoclonal antibody of claim 53 and a detectable label. ~~4~~

Please add new claims 89-99 as follows:

15
--89. (new) A monoclonal antibody of claim 53 which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, such that the antibody competitively inhibits the immunospecific binding of any of the monoclonal antibodies designated 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, respectively, to PSCA of SEQ ID NO: 2.--

--90. (new) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 1G8 to PSCA of SEQ ID NO: 2.--

--91. (new) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 2A2, wherein the antibody

competitively inhibits the immunospecific binding of the monoclonal antibody 2A2 to PSCA of SEQ ID NO: 2.--

--92. (new) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 2H9, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 2H9 to PSCA of SEQ ID NO: 2.--

--93. (new) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 3C5, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3C5 to PSCA of SEQ ID NO: 2.--

--94. (new) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 3E6, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3E6 to PSCA of SEQ ID NO: 2.--

--95. (new) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 3G3, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 3G3 to PSCA of SEQ ID NO: 2.--

--96. (new) A monoclonal antibody of claim 89 which specifically binds to the epitope bound by the monoclonal antibody designated 4A10, wherein the antibody competitively inhibits the immunospecific binding of the monoclonal antibody 4A10 to PSCA of SEQ ID NO: 2.--

--97. (new) A monoclonal antibody which specifically binds to the epitope bound by the monoclonal antibody designated 1G8, 2H9, 3C5, 3E6, or 4A10, produced by

the hybridomas designated HB-12612, HB-12614, HB-12616/ HB-12618, or HB-12617, respectively, as deposited with the American Type Culture Collection.--

--98. (new) A monoclonal antibody which immunospecifically binds the epitope bound by the monoclonal antibody designated 2A2 or 3G3, produced by the hybridomas designated HB-12613, or HB-12615, respectively, as deposited with the American Type Culture Collection.--

--99. (new) A monoclonal antibody which specifically recognizes and binds a portion of a PSCA of SEQ ID. NO. 2, wherein the portion is selected from the group consisting of:

- a. amino acid residues 2 through 50 as described in SEQ ID NO: 2;
- b. amino acid residues 85 through 123 as described in SEQ ID NO: 2;
- c. amino acid residues 46 through 109 as described in SEQ ID NO: 2;
- d. amino acid residues 18 through 98 as described in SEQ ID NO: 2;
- e. amino acid residues 22 through 99 as described in SEQ ID NO: 2;
- f. amino acid residues 21 through 50 as described in SEQ ID NO: 2;
- g. amino acid residues 46 through 85 as described in SEQ ID NO: 2;
- h. amino acid residues 50 through 64 as described in SEQ ID NO: 2;
- i. amino acid residues 67 through 81 as described in SEQ ID NO: 2;
- j. amino acid residues 21 through 99 as described in SEQ ID NO: 2;
- k. amino acid residues 71 through 82 as described in SEQ ID NO: 2;
- l. amino acid residues 85 through 99 as described in SEQ ID NO: 2;
- m. amino acid residues 18 through 50 as described in SEQ ID NO: 2;
- n. amino acid residues 46 through 98 as described in SEQ ID NO: 2; or
- o. amino acid residues 85 through 98 as described in SEQ ID NO: 2.-t

REMARKS